Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China.

ABSTRACT:

Background

There are currently few studies on the efficacy and safety of the dual human epidermal growth factor receptor 2 (HER2)-targeted combination of trastuzumab and pertuzumab in second-line or subsequent therapy of metastatic breast cancer (MBC). This study retrospectively demonstrated the clinical efficacy and side effects of trastuzumab plus pertuzumab in combination with chemotherapy in HER2-positive MBC.

Methods

Patients with HER2-positive MBC and treated with trastuzumab plus pertuzumab combined with chemotherapy at our hospital between August 2013 and October 2021 were included. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were disease control rate (DCR), objective response rate (ORR), clinical benefit rate (CBR), and side

SUBMITTER: Qian Y 

PROVIDER: S-EPMC9469119 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature